STOCK TITAN

Entrada Therapeutics Inc - TRDA STOCK NEWS

Welcome to our dedicated news page for Entrada Therapeutics (Ticker: TRDA), a resource for investors and traders seeking the latest updates and insights on Entrada Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Entrada Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Entrada Therapeutics's position in the market.

Rhea-AI Summary
Entrada Therapeutics, Inc. (TRDA) extends cash runway through Q2 2026 with $352 million in cash, completes dosing for Phase 1 trial of ENTR-601-44 for DMD, plans regulatory applications for Phase 2 development, and reports financial results for Q4 and full year ending December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.76%
Tags
-
Rhea-AI Summary
Entrada Therapeutics, Inc. (Nasdaq: TRDA) will participate in two investor conferences to discuss its intracellular Endosomal Escape Vehicle (EEV™)-therapeutics. CEO Dipal Doshi will join a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, and President Nathan Dowden will participate in the TD Cowen 44th Annual Health Care Conference. Webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
Rhea-AI Summary
Entrada Therapeutics, Inc. (Nasdaq: TRDA) promotes Nathan J. Dowden to President and Chief Operating Officer, effective January 1, 2024. With 30 years of experience in the healthcare sector, Mr. Dowden has been instrumental in guiding Entrada's growth, advancing its lead program, and establishing new headquarters in Boston. He aims to continue driving Entrada's operational growth and making a difference for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.03%
Tags
none
Rhea-AI Summary
Entrada Therapeutics, Inc. (TRDA) completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101. U.S. FDA clinical hold on IND application remains in effect. Cash runway expected through 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.85%
Tags
none
-
Rhea-AI Summary
Entrada Therapeutics, Inc. initiated a Phase 1 clinical trial of ENTR-601-44 for Duchenne muscular dystrophy, expanded its Duchenne franchise, and reported $354 million in cash, cash equivalents, and marketable securities as of September 30, 2023. The company also highlighted recent business updates and financial results for the third quarter ending September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags
-
Rhea-AI Summary
Entrada Therapeutics to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.47%
Tags
conferences
Rhea-AI Summary
Entrada Therapeutics initiates Phase 1 clinical trial for ENTR-601-44 in Duchenne muscular dystrophy patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
-
Rhea-AI Summary
Entrada Therapeutics, Inc. (Nasdaq: TRDA) to participate in two investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.47%
Tags
Entrada Therapeutics Inc

Nasdaq:TRDA

TRDA Rankings

TRDA Stock Data

435.13M
13.57M
15.46%
78.68%
5.26%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Boston

About TRDA

entrada therapeutics is building the leading intracellular biologics company to transform the treatment of devastating diseases. entrada was co-founded in 2016 by 5am ventures, a leading life sciences venture capital firm.